RE:RE:RE:JV with Merck's Keyteuda a bad idea...
You also have to wonder if a Big Pharma when negotiating with TLT, will take into account this huge US$300 billion market exposure (that is a tough and expensive $$$ question?)?
+++++
This is the part of the negotiations which we have entrusted to RDW. Our future success lies with his negotiating abilities.
He's also potentially the greatest obstacle.